Logo image of BCAB

BIOATLA INC (BCAB) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:BCAB - US09077B1044 - Common Stock

0.3222 USD
+0 (+0.81%)
Last: 1/16/2026, 8:00:01 PM
0.3155 USD
-0.01 (-2.08%)
Pre-Market: 1/20/2026, 5:33:43 AM
Fundamental Rating

0

Overall BCAB gets a fundamental rating of 0 out of 10. We evaluated BCAB against 525 industry peers in the Biotechnology industry. BCAB may be in some trouble as it scores bad on both profitability and health. BCAB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year BCAB has reported negative net income.
  • In the past year BCAB has reported a negative cash flow from operations.
  • BCAB had negative earnings in each of the past 5 years.
  • BCAB had a negative operating cash flow in each of the past 5 years.
BCAB Yearly Net Income VS EBIT VS OCF VS FCFBCAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • BCAB's Return On Assets of -438.62% is on the low side compared to the rest of the industry. BCAB is outperformed by 93.52% of its industry peers.
Industry RankSector Rank
ROA -438.62%
ROE N/A
ROIC N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
BCAB Yearly ROA, ROE, ROICBCAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 -200 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BCAB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BCAB Yearly Profit, Operating, Gross MarginsBCAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -10K -20K -30K

More info and screens

0

2. Health

2.1 Basic Checks

  • BCAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for BCAB has been increased compared to 1 year ago.
  • The number of shares outstanding for BCAB has been increased compared to 5 years ago.
  • BCAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
BCAB Yearly Shares OutstandingBCAB Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
BCAB Yearly Total Debt VS Total AssetsBCAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • BCAB has an Altman-Z score of -62.19. This is a bad value and indicates that BCAB is not financially healthy and even has some risk of bankruptcy.
  • BCAB has a worse Altman-Z score (-62.19) than 91.43% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -62.19
ROIC/WACCN/A
WACC8.88%
BCAB Yearly LT Debt VS Equity VS FCFBCAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • BCAB has a Current Ratio of 0.54. This is a bad value and indicates that BCAB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.54, BCAB is not doing good in the industry: 89.71% of the companies in the same industry are doing better.
  • BCAB has a Quick Ratio of 0.54. This is a bad value and indicates that BCAB is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BCAB has a worse Quick ratio (0.54) than 89.52% of its industry peers.
Industry RankSector Rank
Current Ratio 0.54
Quick Ratio 0.54
BCAB Yearly Current Assets VS Current LiabilitesBCAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

2

3. Growth

3.1 Past

  • BCAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.35%, which is quite impressive.
  • Measured over the past years, BCAB shows a quite strong growth in Revenue. The Revenue has been growing by 16.17% on average per year.
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.73%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, BCAB will show a small growth in Earnings Per Share. The EPS will grow by 5.71% on average per year.
  • BCAB is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -14.87% yearly.
EPS Next Y23.5%
EPS Next 2Y16.12%
EPS Next 3Y5.41%
EPS Next 5Y5.71%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BCAB Yearly Revenue VS EstimatesBCAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2024 2M 4M 6M 8M 10M
BCAB Yearly EPS VS EstimatesBCAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • BCAB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year BCAB is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BCAB Price Earnings VS Forward Price EarningsBCAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BCAB Per share dataBCAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.12%
EPS Next 3Y5.41%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for BCAB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

BIOATLA INC

NASDAQ:BCAB (1/16/2026, 8:00:01 PM)

Premarket: 0.3155 -0.01 (-2.08%)

0.3222

+0 (+0.81%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-25
Inst Owners28.64%
Inst Owner Change-0.19%
Ins Owners10.17%
Ins Owner Change-0.64%
Market Cap18.94M
Revenue(TTM)11.00M
Net Income(TTM)-69.78M
Analysts85.71
Price Target10.2 (3065.74%)
Short Float %8.25%
Short Ratio2.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.91%
Min EPS beat(2)7.04%
Max EPS beat(2)10.77%
EPS beat(4)4
Avg EPS beat(4)16.72%
Min EPS beat(4)7.04%
Max EPS beat(4)26.47%
EPS beat(8)8
Avg EPS beat(8)19.05%
EPS beat(12)11
Avg EPS beat(12)14.38%
EPS beat(16)14
Avg EPS beat(16)11.63%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)20.88%
EPS NY rev (1m)0%
EPS NY rev (3m)9.5%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.72
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.15
EYN/A
EPS(NY)-0.94
Fwd EYN/A
FCF(TTM)-0.97
FCFYN/A
OCF(TTM)-0.97
OCFYN/A
SpS0.19
BVpS-0.53
TBVpS-0.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -438.62%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-94.49%
ROA(5y)-67.12%
ROE(3y)-240.96%
ROE(5y)-157.04%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.69
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.54
Quick Ratio 0.54
Altman-Z -62.19
F-Score4
WACC8.88%
ROIC/WACCN/A
Cap/Depr(3y)10.18%
Cap/Depr(5y)31.62%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-22.73%
EPS Next Y23.5%
EPS Next 2Y16.12%
EPS Next 3Y5.41%
EPS Next 5Y5.71%
Revenue 1Y (TTM)N/A
Revenue growth 3Y253.04%
Revenue growth 5Y16.17%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y-14.87%
EBIT growth 1Y42.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.23%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y42.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.02%
OCF growth 3YN/A
OCF growth 5YN/A

BIOATLA INC / BCAB FAQ

What is the ChartMill fundamental rating of BIOATLA INC (BCAB) stock?

ChartMill assigns a fundamental rating of 0 / 10 to BCAB.


What is the valuation status for BCAB stock?

ChartMill assigns a valuation rating of 0 / 10 to BIOATLA INC (BCAB). This can be considered as Overvalued.


Can you provide the profitability details for BIOATLA INC?

BIOATLA INC (BCAB) has a profitability rating of 0 / 10.